Madhav Devani, MD
Hospitalist · Hoover, ALNPI 1538489190
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$524
- AbbVie$497
- Pfizer$438
- Merz North America, Inc.$378
- GSK$238
- Lilly USA, LLC$189
- plus $1K from 26 others
Across 41 payments — averaging $3155.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$91K
- Genentech, Inc.$39K
What the payments were for
- Food & beverage$3,268100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $524 |
| AbbVie | 28 | $497 |
| Pfizer | 29 | $438 |
| Merz North America, Inc. | 13 | $378 |
| GSK | 15 | $238 |
| Lilly USA, LLC | 11 | $189 |
| Exact Sciences | 5 | $151 |
| AstraZeneca | 6 | $95 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Abbott | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Shield Therapeutics Inc | 2 | $46 |
| Amgen | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Irhythm Technologies, Inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Merck | 1 | $19 |
| Avion Pharmaceuticals | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $18 |
| Acelrx Pharmaceuticals, Inc. | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Kaleo, Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
How this compares
$3,268 in reported general payments places this provider in the 95th percentile of 265 hospitalist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $59,542 |
| JardianceEmpagliflozin | 42 | $54,119 |
| EliquisApixaban | 28 | $38,468 |
| RybelsusSemaglutide | 14 | $23,368 |
| MounjaroTirzepatide | 18 | $18,470 |
| XareltoRivaroxaban | 16 | $14,798 |
| FarxigaDapagliflozin Propanediol | 11 | $9,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,433 |
| Atorvastatin Calcium | 205 | $2,274 |
| Levothyroxine Sodium | 160 | $2,037 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 34 | $1,940 |
| Losartan Potassium | 106 | $1,675 |
| Duloxetine Hcl | 20 | $1,368 |
| Rosuvastatin Calcium | 54 | $1,245 |
| Metoprolol Succinate | 96 | $1,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $524 | $82,91067 claims |
| PfizerEliquis | $438 | $38,46828 claims |
| Lilly USA, LLCMounjaro | $189 | $18,47018 claims |
| AstraZenecaFarxiga | $95 | $9,83711 claims |
| GSKTrelegy Ellipta | $238 | $9,43315 claims |
| AbbVieSynthroid | $497 | $1,06411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 hospitalist providers in Alabama.
Other hospitalist in Hoover
- Abilash BalmuriAlabaster$6K
- Aftab KhanBirmingham$5K
- Dennis SehgalDecatur$5K
- Neil ShahTuscaloosa$4K
- Mark CromerBirmingham$4K
- Matthew BurdenBirmingham$4K
- Faheem ShaikhBirmingham$3K
- Kimberly HillmanTuscaloosa$3K
- Sandeep VirkBirmingham$3K
- Daniel FoxHuntsville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.